Incidence of respiratory virus illness and hospitalizations in a Panama and El Salvador birth cohort, 2014-2018.

Child acute respiratory illness Influenza Respiratory viruses

Journal

Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676

Informations de publication

Date de publication:
Sep 2022
Historique:
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 4 10 2022
Statut: ppublish

Résumé

Respiratory viruses remain a key cause of early childhood illness, hospitalization, and death globally.The recent pandemic has rekindled interest in the control of respiratory viruses among paediatric populations. We estimate the burden of such viruses among children <2 years. Enrolled neonates were followed until two years of age. Weekly active symptom monitoring for the development of acute respiratory illnesses (ARI) defined as cough, rhinorrhoea, difficulty breathing, asthenia, anorexia, irritability, or vomiting was conducted. When the child had ARI and fever, nasopharyngeal swabbing was performed, and samples were tested through singleplex RT-PCR. Incidence of respiratory viruses was calculated by dividing the number of laboratory-confirmed detections by the person-time accrued during weeks when that virus was detectable through national surveillance then corrected for under-ascertainment among untested children. During December 2014-November 2017, 1567 enrolled neonates contributed 2,186.9 person-years (py). Six in ten (64·4%) children developed ARI (total 2493 episodes). Among children <2 years, incidence of respiratory syncytial virus (RSV)-associated ARI episodes (21·0, 95%CI 19·3-22·8, per 100py) and rhinovirus-associated (20·5, 95%CI 20·4-20·7) were similar and higher than parainfluenza 1-3-associated (14·2, 95%CI 12·2-16·1), human metapneumovirus-associated (9·2, 95%CI 7·7-10·8), influenza-associated (5·9, 95%CI 4·4-7·5), and adenovirus-associated ARI episodes (5·1, 95%CI 5·0-5·2). Children aged <3 months had the highest rates of RSV ARI (49·1, 95%CI 44·0-54·1 per 100py) followed by children aged 3-5 (25·1, 95%CI 20·1-30·0), 6-11 (17·6, 95%CI 13·2-21·9), and 12-23 months (11·9, 95%CI 10·8-12·9). One in ten children with RSV was referred to the hospital (2·5, 95%CI 2·1-2·8, per 100py). Children frequently developed viral ARI and a substantive proportion required hospital care. Such findings suggest the importance of exploring the value of new interventions and increasing uptake of existing prevention measures to mitigate burden of epidemic-prone respiratory viruses. The study was supported by the Centers for Disease Control and Prevention.

Sections du résumé

Background UNASSIGNED
Respiratory viruses remain a key cause of early childhood illness, hospitalization, and death globally.The recent pandemic has rekindled interest in the control of respiratory viruses among paediatric populations. We estimate the burden of such viruses among children <2 years.
Methods UNASSIGNED
Enrolled neonates were followed until two years of age. Weekly active symptom monitoring for the development of acute respiratory illnesses (ARI) defined as cough, rhinorrhoea, difficulty breathing, asthenia, anorexia, irritability, or vomiting was conducted. When the child had ARI and fever, nasopharyngeal swabbing was performed, and samples were tested through singleplex RT-PCR. Incidence of respiratory viruses was calculated by dividing the number of laboratory-confirmed detections by the person-time accrued during weeks when that virus was detectable through national surveillance then corrected for under-ascertainment among untested children.
Findings UNASSIGNED
During December 2014-November 2017, 1567 enrolled neonates contributed 2,186.9 person-years (py). Six in ten (64·4%) children developed ARI (total 2493 episodes). Among children <2 years, incidence of respiratory syncytial virus (RSV)-associated ARI episodes (21·0, 95%CI 19·3-22·8, per 100py) and rhinovirus-associated (20·5, 95%CI 20·4-20·7) were similar and higher than parainfluenza 1-3-associated (14·2, 95%CI 12·2-16·1), human metapneumovirus-associated (9·2, 95%CI 7·7-10·8), influenza-associated (5·9, 95%CI 4·4-7·5), and adenovirus-associated ARI episodes (5·1, 95%CI 5·0-5·2). Children aged <3 months had the highest rates of RSV ARI (49·1, 95%CI 44·0-54·1 per 100py) followed by children aged 3-5 (25·1, 95%CI 20·1-30·0), 6-11 (17·6, 95%CI 13·2-21·9), and 12-23 months (11·9, 95%CI 10·8-12·9). One in ten children with RSV was referred to the hospital (2·5, 95%CI 2·1-2·8, per 100py).
Interpretation UNASSIGNED
Children frequently developed viral ARI and a substantive proportion required hospital care. Such findings suggest the importance of exploring the value of new interventions and increasing uptake of existing prevention measures to mitigate burden of epidemic-prone respiratory viruses.
Funding UNASSIGNED
The study was supported by the Centers for Disease Control and Prevention.

Identifiants

pubmed: 36189114
doi: 10.1016/j.lana.2022.100304
pii: S2667-193X(22)00121-1
pmc: PMC9485193
doi:

Types de publication

Journal Article

Langues

eng

Pagination

None

Informations de copyright

© 2022 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

NO received travel support from QLife (Ecole Normale Superieure) to attend the Quantitative Viral Dynamics Across Scales Winter School Workshop. All other authors declare that they have no potential conflicts of interest to disclose.

Références

Clin Infect Dis. 2020 May 6;70(10):2029-2035
pubmed: 31257406
JAMA. 2021 Jun 8;325(22):2257-2259
pubmed: 34100881
Vaccine. 2019 Oct 8;37(43):6255-6261
pubmed: 31500965
Vaccine. 2020 Jan 29;38(5):1194-1201
pubmed: 31787411
J Infect. 2022 Feb;84(2):216-226
pubmed: 34953903
Influenza Other Respir Viruses. 2022 Jan;16(1):159-165
pubmed: 34432371
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:13-21
pubmed: 26256291
BMC Infect Dis. 2021 Jan 9;21(1):43
pubmed: 33422002
PLoS Med. 2016 Mar 24;13(3):e1001977
pubmed: 27011229
Hum Vaccin Immunother. 2016 Aug 2;12(8):2206-2214
pubmed: 27196006
PLoS One. 2012;7(2):e32056
pubmed: 22384139
PLoS One. 2019 Sep 6;14(9):e0221479
pubmed: 31490961
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
Endocrinology. 2020 Sep 1;161(9):
pubmed: 32730568
Influenza Other Respir Viruses. 2022 Jan;16(1):24-33
pubmed: 34432362
PLoS One. 2019 May 7;14(5):e0216308
pubmed: 31063477
BMC Infect Dis. 2012 Apr 20;12:95
pubmed: 22520624
Influenza Other Respir Viruses. 2022 Jan;16(1):101-112
pubmed: 34519426
Vaccine X. 2019 Nov 02;3:100047
pubmed: 31867577
Pediatr Infect Dis J. 2011 Jun;30(6):510-7
pubmed: 21487331
Am J Trop Med Hyg. 2021 May 10;105(1):93-101
pubmed: 33970888
BMC Infect Dis. 2015 Oct 24;15:447
pubmed: 26497393
J Infect Dis. 2020 Jan 14;221(3):356-366
pubmed: 31314899
Int J Gynaecol Obstet. 2022 Aug;158(2):359-367
pubmed: 34767628
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
PLoS One. 2015 Sep 02;10(9):e0137454
pubmed: 26331616
Hum Immunol. 2022 Jan;83(1):17-26
pubmed: 34615609
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1305-1309
pubmed: 32941415
PLoS Biol. 2019 Jan 31;17(1):e3000131
pubmed: 30703088
Emerg Infect Dis. 2015 Sep;21(9):1595-601
pubmed: 26292017
PLoS One. 2014 Feb 25;9(2):e89978
pubmed: 24587163
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428

Auteurs

Eduardo Azziz-Baumgartner (E)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lindsey M Duca (LM)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Rosalba González (R)

Gorgas Institute, Panama City, Panama.

Arlene Calvo (A)

Gorgas Institute, Panama City, Panama.
University of South Florida, Panama.

S Cornelia Kaydos-Daniels (SC)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Natalie Olson (N)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Adam MacNeil (A)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Vic Veguilla (V)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Rhina Domínguez (R)

National Institute of Health of El Salvador, El Salvador.

Andrea Vicari (A)

Pan American Health Organization.

Rafael Rauda (R)

National Institute of Health of El Salvador, El Salvador.

Nga Vuong (N)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Alba María Ropero (AM)

Pan American Health Organization.

Julio Armero (J)

National Institute of Health of El Salvador, El Salvador.

Rachael Porter (R)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Danilo Franco (D)

Gorgas Institute, Panama City, Panama.

Juan Miguel Pascale (JM)

Gorgas Institute, Panama City, Panama.

Classifications MeSH